Blue Earth Diagnostics
Blue Earth Diagnostics is an established molecular imaging company on a growth trajectory to provide innovative, well differentiated diagnostics solutions, informing patients and driving future therapies in cancer. Formed in 2014, Blue Earth Diagnostics success is driven by our management expertise and agility, supported by our demonstrated track record of rapid development and commercialization of PET radiopharmaceuticals. Blue Earth Diagnostics clinical focus is exclusively in cancer.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical / Health Care
- Market Focus:
- Globally (various continents)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
About Us
Axumin (fluciclovine (18F)) is our first approved and commercially available product. Axumin is a novel molecular imaging agent approved in the United States and the European Union for use in PET imaging to detect and localize prostate cancer in men with diagnosis of biochemical recurrence. Blue Earth Diagnostics is also investigating fluciclovine (18F) for use in neuro-oncology because fluciclovine has the potential application in imaging cancers other than in prostate cancer.
The company’s pipeline includes innovative radiohybrid Prostate Specific Membrane Antigen (rhPSMA) targeted technology which is a clinical-stage, investigational class of theranostic compounds, with potential applications in both the imaging and treatment of prostate cancer.
Blue Earth Diagnostics’ strategy is to apply its knowledge and expertise to developing promising cancer radiopharmaceuticals for imaging and therapy.
Blue Earth Diagnostics is a subsidiary of Bracco Imaging S.p.A., a global leader in diagnostic imaging.
Mission Statement
Developing precision radiopharmaceuticals for patients with cancer.